CRCM  Vol.4 No.6 , June 2015
Case Study: The Determination of a Complex Multi-Systemic Medical Condition by a Cognitive, Virtual Scanning Technique
ABSTRACT
The study of various medical conditions is limited by the current state of knowledge. New tech-nologies enable researchers to advance their understanding of various medical conditions and to advance their understanding of particular pathologies. Strannik Virtual Scanning (SVS) is such a technology. SVS is able to determine the genetic and non-genetic components of every pathology in each of the 30 main organs, and it is able to determine the onset of pathologies at a much earlier stage than any other technologies or techniques. This makes it an ideal tool to screen for the onset and progression of pathologies which are implicated in multi-systemic conditions and to determine the spectrum of pathologies i.e. comorbidities which are involved in diabetes, cardiovascular disease, migraine, chronic fatigue syndrome, fibromyalgia, depression, chronic kidney disease, etc. This case study illustrates how the technology can be usefully and cost-effectively deployed to determine the spectrum of pathologies which characterise Reynaud’s phenomenon. This includes pathologies in the liver and kidneys e.g. portal hypertension, renal insufficiency, nephritis, liver insufficiency, pre-symptomatic onset of heart attack, presymptomatic indications of dementia, pancreatic cancer, and ovarian cancer, which are difficult to diagnose and/or for which there is currently an unmet clinical need.

Cite this paper
Ewing, G. (2015) Case Study: The Determination of a Complex Multi-Systemic Medical Condition by a Cognitive, Virtual Scanning Technique. Case Reports in Clinical Medicine, 4, 209-221. doi: 10.4236/crcm.2015.46042.
References
[1]   Saigal, R., Kansal, A., Mittal, M., Singh, Y. and Ram, H. (2010) Raynaud’s Phenomenon. JAPI, 58, 309-313.

[2]   Gallaraga, B.J. (2008) Raynaud’s Phenomenon. Synopsis of Causation.
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/
384542/raynauds_phenomenon.pdf


[3]   Goundry, B., Bell, L., Langtree, M. and Moorthy, A. (2012) Diagnosis and Management of Raynaud’s Phenomenon. British Medical Journal, 344, e289.
http://dx.doi.org/10.1136/bmj.e289

[4]   Brown, S. (2012) Diagnosis and Management of Patients with Raynaud’s Phenomenon. Nursing Standard, 26, 41-46.
http://dx.doi.org/10.1002/art.21912

[5]   Hirschl, M., Hirschl, K., Lenz, M., Katzenschlager, R., Hutter, H.-P. and Kundi, M. (2006) Transition from Primary Raynaud’s Phenomenon to Secondary Raynaud’s Phenomenon Identified by Diagnosis of an Associated Disease. Arthritis & Rheumatism, 54, 1974-1981.
http://dx.doi.org/10.1002/art.21912

[6]   Maverakis, E., Patel, F. and Kronenberg, D. (2014) International Consensus Criteria for the Diagnosis of Raynaud’s Phenomenon. Journal of Autoimmunity, 48-49, 60-65.
http://dx.doi.org/10.1016/j.jaut.2014.01.020

[7]   Maricq, H.R. and Weinrich, M.C. (1988) Diagnosis of Raynaud’s Phenomenon Assisted by Color Charts. Journal of Rheumatology, 15, 454-459.

[8]   www.montaguehealthcare.co.uk/OperatingManual.pdf

[9]   Kahan, A., Weber, S., Amor, B., Saporta, L., Hodara, M. and Degeorges, M. (1981) Nifedipine and Raynaud’s Phenomenon. Annals of Internal Medicine, 94, 546.
http://dx.doi.org/10.7326/0003-4819-94-4-546_1

[10]   Ennis, H., Anderson, M.E., Wilkinson, J. and Herrick, A.L. (2014) Calcium Channel Blockers for Primary Raynaud’s Phenomenon. Cochrane Database of Systematic Reviews, 1, CD002069.
http://dx.doi.org/10.1002/14651858.cd002069.pub4

[11]   Waldo, R. (1979) Prazosin Relieves Raynaud’s Vasospasm. JAMA, 241, 1037.
http://dx.doi.org/10.1001/jama.1979.03290360053028

[12]   Pancera, P., Sansone, S., Secchi, S., Covi, G. and Lechi, A. (1997) The Effects of Thromboxane A2 Inhibition (Picotamide) and Angiotensin II Receptor Blockade (Losartan) in Primary Raynaud’s Phenomenon. Journal of Internal Medicine, 242, 373-376.
http://dx.doi.org/10.1046/j.1365-2796.1997.00219.x

[13]   Dziadzio, M., Denton, C.P., Smith, R., et al. (1999) Losartan Therapy for Raynaud’s Phenomenon and Scleroderma: Clinical and Biochemical Findings in a Fifteen-Week, Randomized, Parallel-Group, Controlled Trial. Arthritis and Rheumatism, 42, 2646-2655.
http://dx.doi.org/10.1002/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T

[14]   http://health.costhelper.com/amputation.html

[15]   (2014) RCGP Curriculum 2010. Statement 2.01. The GP Consultation in Practice.
http://www.gmc-uk.org/2_01_The_GP_consultation_in_practice_May_
2014.pdf_56884483.pdf


[16]   Ewing, G.W. (2013) A Comparison of the Diagnostic Scope of Biomarker Techniques, Genetic Screening and Virtual Scanning. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry, 13, 35-45.
http://dx.doi.org/10.2174/1871522211313010004

[17]   http://www.nhs.uk/Conditions/Raynauds-phenomenon/Pages/Introduction.aspx

 
 
Top